What is the 13F Pro Quality Score for ATRC?

13F Pro ranks AtriCure, Inc. (ATRC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ATRC's current score at https://13fpro.ai/research/ATRC (free sign-up required for the full ranking).

Where does 13F Pro source ATRC data?

All AtriCure, Inc. fundamentals and ownership data come directly from SEC EDGAR. AtriCure, Inc. files with the SEC under CIK 1323885. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ATRC in?

AtriCure, Inc. (ATRC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ATRC research updated on 13F Pro?

ATRC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

AtriCure, Inc.(ATRC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1323885 ATRC stock profile & AI dashboard →

13F Pro Quality Score

47.6/100

Rank #1,594 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

75.5/100

Profitability

45.8/100

Balance Sheet

29.5/100

Earnings Quality

30.0/100

Free Cash Flow

48.0/100

Institutional Flow

73.0/100

Revenue Scale

37.8/100

Dilution Risk

19.1/100

ATRC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for AtriCure, Inc. (ATRC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ATRC at 47.6/100 on a 32-signal composite quality model, placing it at rank #1,594 of 2,879 stocks — the bottom half of the AI-ranked universe. ATRC scores in the top quartile across revenue growth (75.5). Areas of concern include balance sheet strength (29.5) and earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 19.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), AtriCure, Inc. reports quarterly revenue of $141.2M, net income of $108.0K, an operating margin of 0.4%. Top institutional holders of ATRC by reported 13-F value include ALLIANCEBERNSTEIN L.P., BlackRock,, WELLINGTON MANAGEMENT GROUP LLP, based on the most recent SEC filings. ATRC trades on the Nasdaq exchange and files with the SEC under CIK 1323885. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ATRC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AtriCure, Inc. directly from SEC EDGAR. AtriCure, Inc.'s 13F Pro composite quality score has ranged between 8 and 65 since 2021, currently 47.6 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about AtriCure, Inc.

Quirks, history, and lore behind ATRC — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on Nasdaq · headquartered in Ohio.
2
The Numbers
Annual revenue in the range of $400–500 million — not a giant, but dominant in its narrow surgical niche with consistent double-digit growth over many years.
3
The History
Founded in the early 2000s, it spun out of research focused on treating cardiac arrhythmias surgically — going after a problem that electrophysiology catheters alone couldn't fully fix.
4
The Secret
Its core technology uses radiofrequency and cryothermal energy to ablate heart tissue — essentially scarring away the electrical misfires that cause atrial fibrillation.
5
The Lore
It pioneered the surgical ablation market and sells systems used in both open-heart and minimally invasive procedures, making it the go-to partner when a patient is already cracked open for another cardiac surgery.
6
The Giveaway
The ticker is basically a cheat code: this company treats atrial fibrillation with surgical ablation devices, and its name is quite literally "Atri-" plus "Cure."

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$141.2M

Net Income

Q1 2026

$108.0K

Free Cash Flow

Q1 2026

$-7.8M

Operating Margin

Q1 2026

0.4%

ROIC

Q1 2026

0.1%

D/E Ratio

Q1 2026

0.12

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+14.9% YoY

$534.5MFY 2025

FY19 $230.8MFY23 $399.2MFY24 $465.3MFY25 $534.5M

Net Income

+74.4% YoY

$-11.4MFY 2025

FY19 $-35.2MFY23 $-30.4MFY24 $-44.7MFY25 $-11.4M

Operating Income

+76.4% YoY

$-9.4MFY 2025

FY19 $-33.1MFY23 $-26.7MFY24 $-40.0MFY25 $-9.4M

EPS (Diluted)

+74.7% YoY

$-0.24FY 2025

FY19 $-0.94FY23 $-0.66FY24 $-0.95FY25 $-0.24

Total Assets

+7.4% YoY

$654.2MFY 2025

FY19 $557.9MFY23 $613.9MFY24 $609.3MFY25 $654.2M

Total Debt

-4.3% YoY

$61.9MFY 2025

FY19 $60.0MFY23 $63.5MFY24 $64.7MFY25 $61.9M

Op. Cash Flow

+369.8% YoY

$57.3MFY 2025

FY19 $-15.8MFY23 $4.5MFY24 $12.2MFY25 $57.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2019	FY 2018	FY 2017
Revenue	$534.5M +14.9%	$465.3M +16.5%	$399.2M +73.0%	$230.8M +14.5%	$201.6M +15.4%	$174.7M
Net Income	$-11.4M +74.4%	$-44.7M -46.8%	$-30.4M +13.5%	$-35.2M -66.5%	$-21.1M +21.4%	$-26.9M
Operating Income	$-9.4M +76.4%	$-40.0M -50.0%	$-26.7M +19.4%	$-33.1M -93.4%	$-17.1M +31.4%	$-25.0M
EPS (Diluted)	$-0.24 +74.7%	$-0.95 -43.9%	$-0.66 +29.8%	$-0.94	—	—
Total Assets	$654.2M +7.4%	$609.3M -0.7%	$613.9M +10.0%	$557.9M +56.4%	$356.8M +33.3%	$267.7M
Total Debt	$61.9M -4.3%	$64.7M +1.8%	$63.5M +5.9%	$60.0M +13.6%	$52.8M +41.1%	$37.4M
Operating Cash Flow	$57.3M +369.8%	$12.2M +172.2%	$4.5M +128.4%	$-15.8M -279.1%	$-4.2M +53.4%	$-8.9M

AI Insight: ATRC Financial Trends

AtriCure reaches operating profitability in Q4 2025 for the first time in the observed period, with revenue up 21% year-over-year to $141M in Q1 2026.

• Revenue grew from $116M in Q2 2024 to $141M in Q1 2026, a sustained upward trajectory across eight consecutive quarters.

• Operating income turned positive at $2M in Q4 2025 and held at $1M in Q1 2026, reversing persistent operating losses.

• Net income improved from -$16M in Q4 2024 to $2M in Q4 2025, reaching near breakeven at $0M in Q1 2026.

• Total debt remained flat at $62M across most quarters, with equity rising from $461M to $492M, indicating no balance sheet deterioration.

⚠ Operating cash flow turned negative at -$4M in Q1 2026, mirroring the -$11M in Q1 2025; Q1 seasonality warrants monitoring.

⚠ Operating profitability is nascent — just $1M–$2M in the latest two quarters; any revenue deceleration could quickly reverse gains.

AI Insight: ATRC Ratio Trends

AtriCure crossed into operating profitability in Q3 2025 for the first time in the dataset, sustaining positive margins through Q1 2026 after a steep Q4 2024 trough.

• Operating margin improved from -11.7% in Q4 2024 to +1.8% in Q4 2025 and +0.4% in Q1 2026 — a dramatic multi-quarter recovery.

• ROIC turned positive at 0.1% in Q3 2025 and reached 1.8% in Q4 2025, ending a string of negative readings dating back to Q2 2024.

• Leverage (D/E) held steady at 0.12–0.14 throughout the period, showing no balance sheet deterioration during the loss phase.

• TTM net profit margin of -0.8% remains negative, reflecting the drag of earlier loss quarters despite recent improvement.

⚠ Q1 2026 operating margin slipped to 0.4% from Q4 2025's 1.8% — monitor whether this is seasonal softness or a trend reversal.

⚠ All profitability metrics only turned marginally positive; any revenue shortfall or cost pressure could quickly flip margins negative again.

Get alerted when ATRC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for AtriCure, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ATRC

ALLIANCEBERNSTEIN L.P.
$128.9M3,258,872 sh
BlackRock, Inc.
$115.3M4,042,681 sh
WELLINGTON MANAGEMENT GROUP LLP
$96.5M3,382,555 sh
Hood River Capital Management LLC
$88.9M3,117,545 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$77.1M2,702,632 sh
VANGUARD CAPITAL MANAGEMENT LLC
$61.5M2,155,764 sh
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.
$51.5M1,804,927 sh
GOLDMAN SACHS GROUP INC
$47.6M1,667,166 sh
MARSHALL WACE, LLP
$41.9M1,467,524 sh
STATE STREET CORP
$37.2M1,302,162 sh

Fund	Value	Shares
ALLIANCEBERNSTEIN L.P.	$128.9M	3,258,872
BlackRock, Inc.	$115.3M	4,042,681
WELLINGTON MANAGEMENT GROUP LLP	$96.5M	3,382,555
Hood River Capital Management LLC	$88.9M	3,117,545
VANGUARD PORTFOLIO MANAGEMENT LLC	$77.1M	2,702,632
VANGUARD CAPITAL MANAGEMENT LLC	$61.5M	2,155,764
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.	$51.5M	1,804,927
GOLDMAN SACHS GROUP INC	$47.6M	1,667,166
MARSHALL WACE, LLP	$41.9M	1,467,524
STATE STREET CORP	$37.2M	1,302,162

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ATRC on your watchlist

Track score changes the day AtriCure, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ATRC a good stock to buy?

13F Pro's AI-powered analysis of AtriCure, Inc. (ATRC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ATRC are available on the ATRC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ATRC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ATRC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AtriCure, Inc.'s investment landscape.